Newsletter · · Ashutosh Agarwal

Obesity Race Shifts to Pills as Novo Nordisk Concedes Ground to Lilly - Weekly Pharma / Biotech / Life Sciences Podcast Recap - Week of September 13, 2026

Weekly Pharma / Biotech / Life Sciences Podcast Recap for the week of September 6 to September 13, 2026. Podcast synthesis on Novo Nordisk's CEO conceding obesity share to Eli Lilly while betting on the oral Wegovy pill, the Lp(a) and IL-6 cardiovascular trial failures at Novartis and Novo, China's rise as a source of biotech deals, and the week's sharpest debate over whether AI drug discovery is real.

Weekly Pharma / Biotech / Life Sciences Podcast Recap

Week of September 13, 2026: Obesity Race Shifts to Pills as Novo Nordisk Concedes Ground to Lilly

The obesity-drug and China-biotech conversations were unusually rich this week, with a sitting Novo Nordisk CEO interview and a detailed venture investor's field report from Shanghai. Cardiovascular drug development, by contrast, had a genuinely bad week, and a lot of podcasts spent time trying to explain why.

1. Dominant Themes

The obesity-drug race has moved from "how much weight" to "which pill, at what price, for whom." The single most-covered topic of the week was GLP-1s, and the conversation has clearly shifted. Novo Nordisk's CEO, Mike Doustdar, sat for a candid interview and openly admitted the company lost ground to Eli Lilly, whose product delivered 21-22% weight loss while Novo's older Ozempic/Wegovy sat at 15-16%. His fix: a higher-dose Wegovy (7.2mg, branded "Wegovy HD") that matches Lilly on weight loss, plus a new oral Wegovy pill that he says is taking "9 out of 10 patients that want a pill" and hit 5 million prescriptions in six months, which he called "the best product launch of any pharmaceutical company to date in volume" (Power Players with Brian Sozzi). The obesity pill is becoming the battleground, and a new small-molecule challenger showed up this week: Structure Therapeutics reported up to 16.2% mean weight loss at 72 weeks for its once-daily oral drug alenaglipron, with more than one in three high-dose patients losing over 20% of their body weight (numbers that, until recently, were only possible with injections) (On The Pen GLP-1 News).

Cheaper access is arriving fast, and the government is now a buyer. On the policy side, CMS Administrator Mehmet Oz said GLP-1s are now available to some Medicare beneficiaries at $50 a month, down from a historical price of "over $1,000", and that more than 600,000 people joined the program in its first two months. He also cited Bank of America spending roughly $250 million a year on GLP-1s for its own employees, up from zero four or five years ago, and claimed the drugs are behind "the first decrease in obesity rates in modern American history" (Squawk Pod). The cash-pay, direct-to-consumer channel is now a real market too: roughly 10 virtual metabolic-health companies prescribing GLP-1s generate about 6.3 million yearly subscribers and $4 billion in annual revenue (Edge Perspectives).

Cardiovascular drug development had a brutal week, and it hit two of the biggest names. Novartis's closely watched Phase 3 outcomes trial for a drug targeting lipoprotein(a), or "Lp(a)" (an inherited, hard-to-treat risk factor for heart disease that affects roughly one in five people), failed. Around the same time, Novo Nordisk halted two more cardiovascular studies of its anti-inflammation drug ziltivekimab (which targets a protein called IL-6) after an independent monitoring board judged they were unlikely to succeed. The theme running through both: the industry has been chasing "residual risk" (the heart attacks that still happen even when patients are on statins and everything else), and two genetically-validated targets just didn't pay off in real trials (The Readout Loud).

China is now discussed as a biotech superpower, not just a cheap factory. Multiple podcasts converged on this. Pharma dealmaking is increasingly flowing to China: over the past 12 months, China has become roughly as important a source of licensing deals as all of Europe, though notably nobody is actually acquiring Chinese companies outright (BioCentury This Week). A venture investor who just toured Shanghai described it as a career-defining "phase shift," comparing the moment to first seeing the AI breakthroughs of 2017 (Newcomer Pod). And a healthcare-focused China episode laid out the dependency risk plainly: China holds about 50% of the world's capacity for active pharmaceutical ingredients (the core chemical building blocks of drugs) (The Prof G Pod with Scott Galloway).

Tariffs and reshoring are a slow-motion story with a hard 2028 deadline. A generic-drug "tariff cliff" is scheduled for 2028 (escalating to 200% the following year) to push manufacturing back to the US. The blunt verdict from a supply-chain consultant: tariffs are "a good start" but nowhere near enough on their own, given the labor-cost gap with India, the capital needed to build factories, and the fact that reshoring active-ingredient production is even harder than reshoring the finished pills, a three-to-five-year-plus job (Off Script: A Pharma Manufacturing Podcast).

The FDA is signaling stability after 18 months of chaos. The agency named permanent directors for its two most important centers: Karim Mikhail at the biologics center (CBER) and Mike Davis at the drugs center (CDER), after both had been "acting" since a leadership meltdown in May 2025 (CDER alone had five directors or acting directors in 2025). But a second, quieter story is that the FDA has almost stopped holding public advisory committee meetings, which regulatory reporters see as a real loss of transparency (Citeline Podcasts).

Drug pricing policy ("Most Favored Nation") is reshaping the whole industry. The Trump administration's push to tie US drug prices to the lowest price paid abroad ("MFN") is now, per the administration, covering "90% of all branded products sold in America" (Squawk Pod). The nuance that matters for investors: several companies got carve-outs, and some large names are resisting entirely (BioCentury This Week).

AI drug discovery: real progress, real skeptics. More on the debate below, but the theme itself was everywhere, from a former Salesforce chief scientist arguing biotechs will soon go public with "eight-plus" drugs instead of one (The MAD Podcast with Matt Turck), to a contrarian ex-rocket-scientist arguing that machine learning is fundamentally the wrong tool (AI For Pharma Growth).

Gene therapy's safety spotlight is back on. A landmark study extended CRISPR gene editing into young children, but also included a death, a reminder that these cures still carry serious risks (NEJM This Week). Details below.

The patent cliff is looming. One healthcare podcast framed the coming wave of patent expirations as more than $500 billion in annual drug sales going off-patent, which will invite biosimilar and generic competition and pull prices down (Health:Further). That same episode floated rough per-company patent-exposure figures for Lilly, Novo, and Pfizer, but the numbers were presented loosely and without clear time framing, so treat them as color rather than hard data.

2. Active Debates

Lilly vs. Novo on obesity: is Novo actually catching back up? Novo's CEO made an optimistic case: match Lilly on weight loss with the higher dose, then win on the extra heart/kidney/liver benefits he argues are unique to Novo's molecule, plus the convenience of a pill. He pushed back directly on impatient investors: "most people, including probably Goldman, will tell you 90% market share is a pretty good one… the market sometimes is, is they're too impatient" (Power Players with Brian Sozzi). The bear side of this debate is implicit in the same interview: the admission of lost share is real, and the Street wants faster pill uptake before it believes the comeback.

Oral vs. injectable GLP-1, and whether small molecules break the price. The clinical education crowd noted that Lilly's oral drug orforglipron beat oral semaglutide on blood-sugar control (1.74% A1C reduction) in a head-to-head trial with fewer gastrointestinal side effects (CME in Minutes: Education in Primary Care). The bigger investment debate, though, is about economics: a non-peptide small-molecule pill that reaches mid-teens weight loss is "just as easy to manufacture," which could pull many more manufacturers into the market and drive prices down. As the host put it, "what happens if obesity drugs increasingly start to look like conventional pills? What does that do to supply… and eventually, what does this do to price?" (On The Pen GLP-1 News).

Is AI drug discovery real or hype? This was the week's sharpest two-sided debate. The bull: Richard Socher argued the whole biotech business model is changing: instead of a company spending eight to ten years to reach late-stage trials with one drug (and dying if it fails), "within six to 18 months [companies] have multiple different drugs in like late stage two trials… by the time they'll go public, it'll be with like eight plus different drugs." He does not believe in an overnight "hard takeoff," because biology "just takes longer" and trials still take years (The MAD Podcast with Matt Turck). The bear: Dr. Jacek Macik of BioDynLab argued machine learning hits a wall of physics: his "principle of incompatibility" holds that "high precision is incompatible with high complexity," so "it doesn't matter how many gigawatts you throw at a problem." He noted AI can cut early-stage lab time (his physics-based method reduced antimicrobial lab time 50-70% with no machine learning) but that human trial failure rates haven't improved despite billions spent (AI For Pharma Growth).

China: existential threat or the whole pie growing? BioCentury's data-driven take pushed back on the "China rising at America's expense" narrative: the number of US biotech deals also rose sharply, so "the whole pie grew" rather than pharma abandoning the US for China (BioCentury This Week). The Newcomer investor was more alarmed on the technology trajectory but careful on drugs specifically, and a China health expert on Prof G was explicit: "in this field, I wouldn't say China is winning yet" on AI-driven drug development, even as she predicted China will run more clinical trials than North America by 2030 (The Prof G Pod with Scott Galloway).

Do tariffs actually bring manufacturing home? The reshoring skeptic case was made forcefully: tariffs help, but without solving labor costs, capital investment, working-capital burdens, regulatory site-transfer timelines, and a skilled workforce, "two years… I don't think that's enough time" to move it all back before the 2028 cliff (Off Script).

Should the government pay for GLP-1s? On Squawk Pod, the hosts debated whether the long-term savings from GLP-1s accrue to employers (who may lose the employee before the payoff) or to the government/society. Dr. Oz's argument: catch patients early, and if the average American works even "one extra year… that's worth $1 trillion to our GDP every year" (Squawk Pod).

Is cardiovascular's residual-risk thesis wrong, or were the trials wrong? After the Novartis and Novo failures, UCSF cardiologist Ethan Weiss laid out the three possibilities cleanly: "One is that this was just a crappy drug. Two was we designed the wrong experiment… And three was the hypothesis is wrong." His own worry was that human genetics tells you what happens over a lifetime, "It doesn't tell you what happens in a short-term trial in people who are on a lot of other really powerful medicines" (The Readout Loud).

3. Stock-by-Stock: Bull and Bear as Articulated on the Podcasts

Eli Lilly (LLY), Bull: The clear obesity winner. Even a competitor's CEO praised its 21-22% weight-loss efficacy and pill momentum (Power Players). Lilly was also the dominant dealmaker in pharma, signing about 40% of the deals in BioCentury's 12-month survey, more than double its nearest peers (GSK, Novartis, Sanofi tied for second), funded by its obesity cash machine (BioCentury This Week). Bear: Its oral orforglipron shows more modest weight loss (~11%) than injectables, and cheap small-molecule competition (like Structure's) is coming for exactly that segment (On The Pen). Lilly shares also ticked down ~2% (about $25 billion of market value) on the read-across from the Lp(a) failures, since it too has an Lp(a) program (BioCentury This Week).

Novo Nordisk (NVO), Bull: The CEO's turnaround plan is concrete: Wegovy HD matches Lilly on weight loss, the oral Wegovy pill hit 5 million scripts in six months with ~90% share of pill-choosers, and CagriSema (semaglutide plus amylin) is coming. He argues Novo's molecule has genuinely differentiated heart/kidney/liver benefits competitors can't replicate (Power Players). Bear: Management openly conceded lost market share; its cardiovascular anti-inflammation bet (ziltivekimab, IL-6) just failed and two more trials were halted (The Readout Loud); and one podcast flagged Novo as among the most exposed to the coming patent cliff (Health:Further).

Novartis (NVS), Bull: Deal-savvy and hedged: it had already licensed siRNA (gene-silencing) programs from China's Argo Biopharma for $160 million and $185 million upfront across 2024-2025, one of which produced DII-235, an Lp(a)-targeting drug now in Phase 2 with data due next year. Analysts read this as a smart hedge against its own troubled Lp(a) program (BioCentury This Week). Bear: A genuinely rough stretch: the big Phase 3 Lp(a) outcomes trial (pelacarsen) failed; a neuromuscular drug (for DM1) from its ~$12 billion Avidity acquisition failed; and it had to pause autoimmune CAR-T trials after patient deaths that the company did not proactively disclose (three deaths surfaced only after a reporter asked) (The Readout Loud).

Amgen (AMGN), Bear: Shares fell about 9% (roughly $21 billion of market value) on the Lp(a) read-across, since Amgen has its own Lp(a) drug in development and the field's setback raised doubts (BioCentury This Week). Bull: On the pipeline, Amgen's tarlatamab (brand name Imdelltra) combined with durvalumab met its primary overall-survival endpoint in the Phase 3 DeLLphi-305 study for first-line extensive-stage small cell lung cancer, a meaningful win in a hard-to-treat cancer (OncoPharm).

Moderna (MRNA), Bull: The Merck/Moderna personalized mRNA cancer vaccine slowed the return and spread of melanoma in a late-stage trial. Preliminary data cited a 59% improvement and a 49% reduction in the risk of recurrence or death; the news "sent Moderna stock through the roof" and revived optimism around mRNA after a period of backlash (The Immunology Podcast; also discussed on The Readout Loud). Bear: Those numbers came only from a press release: "no data yet," as Readout Loud noted.

Vertex (VRTX) / CRISPR Therapeutics (CRSP), Bull/Bear (safety in focus): Their CRISPR-edited cell therapy EXA-CELL (exagamglogene autotemcel) was extended into children aged 5-11 (15 with transfusion-dependent beta-thalassemia and 11 with sickle cell disease), achieving transfusion independence or freedom from severe pain crises over 16+ months of follow-up. But the safety flag is serious: all participants had grade 3 or 4 adverse events, two children developed severe veno-occlusive liver disease tied to the chemotherapy conditioning (busulfan), and one child died. The accompanying editorial argued this makes the case for in-vivo approaches that avoid harsh conditioning (NEJM This Week).

Neurocrine Biosciences (NBIX), Bear: Vykat XR, the Prader-Willi syndrome drug it gained by acquiring Soleno Therapeutics, is now showing side effects, toxicity, and deaths in real-world use that weren't picked up in the smaller approval trials, a cautionary tale about rare-disease drugs after launch (The Readout Loud).

Sanofi (SNY), Bull: Its multiple myeloma drug Sarclisa (isatuximab) succeeded in the Phase 3 ERACLEA trial testing a subcutaneous, on-body-injector version against the IV formulation, hitting dual endpoints for non-inferior efficacy with significantly fewer infusion and injection-site reactions, a convenience/differentiation win (DoctorPodcasts || Cykiert Files). Sanofi is also active in China licensing (partnering with AI-biotech Helixon) (Newcomer Pod).

Structure Therapeutics (GPCR), Bull: Its oral small-molecule GLP-1 alenaglipron posted up to 16.2% weight loss at 72 weeks with over a third of high-dose patients losing 20%+, and under 5% discontinuing for side effects after a slower dose ramp, putting an oral into injectable territory. It also has an oral amylin candidate (ACCG2671) with a long (~6-day) half-life that could allow weekly dosing (On The Pen GLP-1 News). Bear: The higher-dose (45mg) data was "messy," with a plateau and even some weight regain, so the dose-response story isn't clean; the amylin data came from just six people, all of whom experienced nausea and vomiting, raising the question of how much of the weight loss is real pharmacology versus patients being "too sick to eat" (On The Pen). Top-line Phase 3 data isn't expected until the second half of 2028.

Exelixis (EXEL), Context/Bull: A founder's-story episode revisited how cabozantinib (Cabometyx) failed in glioblastoma but succeeded in kidney and liver cancer: the METEOR trial in renal cell carcinoma hit all three efficacy endpoints in 2015, leading to its first approval, a case study in a persistence-driven oncology franchise (Nucleate Podcast).

Compass Pathways (CMPS), Bull/Catalyst: Its synthetic psilocybin for treatment-resistant depression is on a rolling FDA submission, with approval expected within roughly 6-9 months (The Journal of Clinical Psychiatry Podcast).

Incyte (INCY), BridgeBio (BBIO), and the MFN holdouts (Vertex, Biogen, Alnylam), Context: On drug-pricing policy, Incyte quietly signed an MFN deal (aligning state Medicaid prices for Jakafi to an international benchmark) but hasn't committed future launches; BridgeBio secured a forward-looking exclusion because its pipeline is entirely orphan drugs; and Vertex, Biogen, and Alnylam are reportedly under pressure to sign MFN deals but so far are resisting (BioCentury This Week).

Biogen (BIIB) & Novartis (NVS) CEOs, Context: Both CEOs gave televised interviews touching on M&A strategy and AI as a productivity tool for finding clinical-trial patients (Squawk on the Street).

4. Notable Quotes

"Is it hard to acknowledge that we lost market share? It's not fun. It's five people that could have been on a GLP-1 that were losing weight, but at the same time protecting their heart, kidney and liver." (Novo Nordisk CEO Mike Doustdar, Power Players with Brian Sozzi)

"We have created a situation where six months into the launch, we just announced 5 million prescriptions. To put that in perspective for you, that's the best product launch of any pharmaceutical company to date in volume." (Mike Doustdar, on the oral Wegovy pill, Power Players with Brian Sozzi)

"One is that this was just a crappy drug. Two was we designed the wrong experiment… And three was the hypothesis is wrong." (Cardiologist Ethan Weiss, on the three explanations for the Lp(a) trial failure, The Readout Loud)

"Now we have companies that instead of having one molecule or drug after eight years in late stage trials, they actually within six to 18 months have multiple different drugs in like late stage two trials already. And by the time they'll go public, it'll be with like eight plus different drugs." (Richard Socher, on how AI changes the biotech model, The MAD Podcast with Matt Turck)

"High precision is incompatible with high complexity. You can't have both at the same time. That's a law of nature, really… it doesn't matter how many gigawatts you throw at a problem." (Dr. Jacek Macik, the contrarian case against ML in drug discovery, AI For Pharma Growth)

"There was my life before, you know, transformer models and after, and in a lot of ways I kind of think of my life before Shanghai 2025 and after Shanghai 2025." (investor Zavain Dar on China's biotech/AI surge, Newcomer Pod)

"GLP-1 medications… are now sold to some Medicare beneficiaries under our new program at $50 a month. $50 a month, that's compared to over $1,000, which was the historical price. We have over 600,000 people who have joined this program for Medicare in the last two months." (CMS Administrator Mehmet Oz, Squawk Pod)

"It was only later on after a reporter reached out to Novartis did the company reveal that there were actually three deaths." (on the undisclosed autoimmune CAR-T trial deaths, The Readout Loud)

"I don't think that's enough time. No, no, I don't." (supply-chain consultant Tom Strohl, on whether two years is enough to reshore generic manufacturing before the 2028 tariff cliff, Off Script)

5. Catalysts to Watch

  • Structure Therapeutics (GPCR): two Phase 3 trials of oral GLP-1 alenaglipron enrolling now, with top-line data expected in the second half of 2028 (On The Pen). Next-step amylin (ACCG2671) data from multiple-ascending-dose testing, including a cohort stacking it on top of existing GLP-1 therapy.
  • Novartis (NVS): DII-235, its China-licensed siRNA Lp(a) drug, has Phase 2 data due next year, the read-through on whether Novartis stays in the Lp(a) game after pelacarsen's failure (BioCentury This Week).
  • Merck / Moderna (MRNA): actual trial data (beyond the press release) on the personalized melanoma cancer vaccine (The Readout Loud).
  • Compass Pathways (CMPS): FDA decision on synthetic psilocybin for treatment-resistant depression, expected within ~6-9 months (The Journal of Clinical Psychiatry Podcast).
  • Drug pricing (MFN): the Medicare pricing models "GLOBE" (Part B) and "GUARD" (Part D): GLOBE has slipped from October 1; watch for both potentially starting January 1, followed quickly by litigation. The list of MFN holdouts (Vertex, Biogen, Alnylam) is the one to monitor for capitulation (BioCentury This Week).
  • Tariffs / reshoring: the 2028 generic tariff cliff (rising to 200% the following year); watch capital-spending announcements for new US API and finished-dose plants, several expected to lean heavily on robotics and AI (Off Script).
  • FDA: confirmation of commissioner nominee Heidi Overton (which could bring new center directors), a possible new deputy commissioner overseeing all medical-product centers, and whether product advisory committees resume. Watch Vanda's five-day public evidentiary hearing on its jet-lag drug (Hetlioz) in December (Citeline Podcasts).
  • China clinical-trial share: the multi-year trend to watch is China's clinical-trial volume, forecast to overtake North America by 2030 (The Prof G Pod).